Tagrisso is a medication that has been approved by the FDA for the treatment of non-small cell lung cancer (NSCLC) that has a specific genetic mutation known as EGFR T790M. This mutation can make the cancer cells resistant to other treatments, but Tagrisso works by targeting this mutation and inhibiting the growth of cancer cells.

As a medical professional, I have seen firsthand the positive impact that Tagrisso can have on patients with NSCLC. It has been shown to significantly improve progression-free survival and overall survival rates in clinical trials, making it a valuable option for patients who have not responded to other treatments.

It is important to note that Tagrisso is not without side effects, like any medication. Common side effects may include diarrhea, rash, and changes in liver function tests. However, these side effects are usually manageable and can be monitored closely by healthcare providers.

Before starting Tagrisso, it is important for patients to discuss their medical history and any other medications they may be taking with their healthcare provider. This will help ensure that Tagrisso is the right treatment option for them and that any potential drug interactions are identified.

Overall, Tagrisso is a promising treatment option for patients with NSCLC who have the EGFR T790M mutation. It has the potential to improve outcomes and quality of life for these patients, and I am confident in recommending it as a valuable addition to our treatment arsenal.